IDEXX Laboratories, Inc. $IDXX Shares Purchased by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 61.5% during the first quarter, HoldingsChannel reports. The firm owned 5,793 shares of the company’s stock after purchasing an additional 2,205 shares during the period. CHICAGO TRUST Co NA’s holdings in IDEXX Laboratories were worth $3,255,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Beacon Investment Advisory Services Inc. boosted its holdings in shares of IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after purchasing an additional 6,710 shares during the last quarter. Nordea Investment Management AB grew its position in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after purchasing an additional 8,845 shares in the last quarter. Procyon Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $1,966,000. Diversified Trust Co. increased its holdings in shares of IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after purchasing an additional 2,901 shares during the last quarter. Finally, Mirabella Financial Services LLP increased its holdings in shares of IDEXX Laboratories by 156.2% in the third quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock valued at $2,806,000 after purchasing an additional 2,683 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IDXX shares. UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Finally, Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Up 2.1%

Shares of IDXX opened at $537.58 on Thursday. The company’s 50-day moving average price is $555.94 and its 200 day moving average price is $610.55. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a market cap of $42.40 billion, a P/E ratio of 39.59, a price-to-earnings-growth ratio of 2.88 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the firm posted $2.91 earnings per share. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.